WO2012088276A2 - Fabrication de phospholipides et manipulation de composition par manipulation de milieu - Google Patents

Fabrication de phospholipides et manipulation de composition par manipulation de milieu Download PDF

Info

Publication number
WO2012088276A2
WO2012088276A2 PCT/US2011/066499 US2011066499W WO2012088276A2 WO 2012088276 A2 WO2012088276 A2 WO 2012088276A2 US 2011066499 W US2011066499 W US 2011066499W WO 2012088276 A2 WO2012088276 A2 WO 2012088276A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
fermentation medium
enzyme
lipids
phospholipids
Prior art date
Application number
PCT/US2011/066499
Other languages
English (en)
Other versions
WO2012088276A3 (fr
Inventor
Joseph Miller
John R. Palmer
Original Assignee
J3H, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J3H, Inc filed Critical J3H, Inc
Publication of WO2012088276A2 publication Critical patent/WO2012088276A2/fr
Publication of WO2012088276A3 publication Critical patent/WO2012088276A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6481—Phosphoglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/02—Other edible oils or fats, e.g. shortenings, cooking oils characterised by the production or working-up
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B1/00—Production of fats or fatty oils from raw materials
    • C11B1/10—Production of fats or fatty oils from raw materials by extracting
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B3/00—Refining fats or fatty oils
    • C11B3/006—Refining fats or fatty oils by extraction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/12—Unicellular algae; Culture media therefor

Definitions

  • the invention relates to phospholipid production via culturing microorganisms, and more specifically to phospholipid production and composition manipulation through chemical, biochemical, and enzymatic additions to the fermentation medium.
  • the phospholipids can comprise saturated or unsaturated omega-3, -6, and/or -9 fatty ackJ side chains.
  • Phospholipids are important components to the human diet, since they deliver more bioavailability of general omega-3 fatty acids, such as EPA and DHA, than glycerides and esters.
  • general omega-3 fatty acids such as EPA and DHA
  • the importance of omega-3 fatty acids to the human diet has been well documented.
  • DHA and EPA have been linked to decreased risk of Alzheimer's disease, decreased risk of certain cancers, and decreased risk of cardiovascular disease, as well as promoting general health in these areas. Further, DHA is used as a supplement to infant formula and prenatal vitamins for improved cognitive development and visual acuity.
  • EPA has been linked to decreases in inflammation and as a treatment for schizophrenia.
  • DHA and EPA primarily originate from marine animal origins or microalgae. Lipids derived from certain marine animals, such as krill, Mysis, and marine roe and milt, deliver more bioavailability of general omega-3s (including DHA and EPA) bonded to phospholipids, however, they are delivered in low levels (less than 35% by weight of total lipids) or low purities (less than 45% phospholipids per gram of oil). Further, EPA and DHA supplied in high concentrations (up to 90% total by weight) are in the form of glycerides or esters, which are not as readily absorbed by the digestive system or cellular structure.
  • Nitrogen starvation during fermentation of marine microorganisms is well known to increase the concentrations of omega-3 fatty acids in the neutral lipid fraction.
  • U.S. Patent No. 5,340,594 discusses nitrogen limitation during fermentation to curb cell growth and to increase omega-3 fatty-acid production. The nitrogen limiting conditions are run for about 6 - 24 hours and the microorganisms are harvested at this time to maximize the amount of omega-3 fatty acids in non-polar lipid form.
  • Phospholipids are becoming increasingly valuable for not only their ability to deliver more bioavailable general omega-3 fatty acids but also for their ability to form unique liposome structures. These liposome structures are valuable in the targeted therapy, biologies, gene therapy, and individualized medicine industries.
  • the current art is not focused on phospholipid production, and especially to methods of enhancing phospholipid production during microorganism fermentation.
  • the art is not focused on creating tailored phospholipids with desired fatty acid and polar group components during microbial oil production. Instead, the art is focused on producing higher concentrations of omega-3 fatty acids in neutral lipid form.
  • Phospholipids are usually treated as a byproduct of neutral lipid production and either land-filled or used as animal feed in the aquacuiture industry because of their high functional (binding) or caloric content. (0006] Therefore, it is desirable to create a method of producing a microbial oil comprising high concentrations of phospholipids, and with specific fatty acid chains and polar groups. Such a method would create higher fractions of phospholipids and would eliminate the need to conduct separate esterfication, transesterfication, or acylation steps, after separating the phospholipids from the microbial oil, to create a phospholipid with desired fatty acid chains and polar groups. It is also desirable to use the phospholipids in manufacturing dietary supplements and liposomes. Such products would be beneficial in the nutraceutical and drug deliver industries.
  • the invention disclosed herein provides a method for culturing a microorganisms, such as microalgae, yeast, bacterial, or fungi, to produce a microbial oil comprising both neutral lipids and polar lipids.
  • the polar lipids can comprise phospholipids. Further, when optimized, the polar lipids can be present at a higher weight percent than the neutral lipids.
  • the method comprises adding to the fermentation medium an additional nitrogen source and optionally whole and/or protein fractions while culturing the microalgae.
  • the additional nitrogen source shifts the microbial oii production towards polar lipids, while the whole and/or protein fractions shift the phospholipid product towards a desired polar group, such as serine.
  • the nitrogen source and protein source can be the same or different component.
  • Additional components such as transferase enzymes, esterase enzymes, and phosphodiesterase enzymes may be added to the fermentation medium to assist in the production of phospholipids with tailored fatty acid and polar groups.
  • the method comprises: (a) culturing a microorganism in a fermentation medium; (b) producing a microbial oil comprising neutral lipids and polar lipids; (c) extracting said microbial oil from said fermentation medium; and (d) separating said polar lipids from said neutral lipids; wherein said fermentation medium comprises an additional nitrogen source and optionally whole proteins or protein fractions.
  • the polar lipids can comprise phospholipids.
  • the microorganism can be microalgae, yeast, bacteria, or fungi.
  • the fermentation medium can also comprise enzymes.
  • a phospholipid composition comprising phospholipids derived from fermenting microorganisms in the presence of an additional nitrogen source and optionally whole proteins or protein fractions.
  • a lipid composition comprising the above phospholipids and a structured lipid.
  • the structured lipid can comprise tailored phospholipids.
  • the structured lipid further comprises a first fatty acid carbon chain derived from a first lipid source, a second fatty acid carbon chain derived from a second lipid source, and a third fatty acid carbon chain derived from a third lipid source.
  • the lipid sources can be plant based, marine animal based, or marine plant based.
  • R 1 -acyl / R 2 -acyl Refers to a carbon chain with the terminal carbon part of the carbonyl group that makes up the acyl.
  • C16 Refers to a carbon chain with 16 carbons.
  • CtBj Refers to a carbon chain with 18 carbons.
  • C20 Refers to a carbon chain with 20 carbons.
  • C22 Refers to a carbon chain with 22 carbons
  • Omecia-3 Fattv Acids A family of unsaturated fatty acids that have in common a final carbon-carbon double bond in the n-3 position; that is, the third bond from the methyl end of the fatty acid, including:
  • DHA Docosahexaenoic acid.
  • ALA a-Linolenic acid
  • Omeaa-6 Fattv Acids A family of unsaturated fatty acids that have in common a final carbon-carbon double bond in the n-6 position; that is, sixth bond counting from the end opposite the carboxyl group of the fatty acid, including:
  • GLA Gamma-linolenic acid
  • DGLA Dihomo-gamma-linolenic acid
  • DPA Docosapentaenoic acid
  • Omeqa-9 Fattv Acids A family of unsaturated fatty acids that have in common a final carbon-carbon double bond in the n-9 position; that is, ninth bond counting from the end opposite the carboxyl group of the fatty acid.
  • a method of producing phospholipids comprises: (a) culturing a microorganism in a fermentation medium; (b) producing a microbial oil comprising neutral lipids and polar lipids; (c) extracting said microbial oil from said fermentation medium; and (d) separating said polar lipids from said neutral lipids; wherein said fermentation medium comprises an additional nitrogen source and optionally whole proteins or protein fractions.
  • the polar lipids can comprise phospholipids and can be present at a higher weight percent than said neutral lipids in said microbial oil.
  • lipid fraction of the microbial oil can range from about 40 wt.% to about 70 wt.% neutral lipids, from about 25 wt.% to about 55 wt.% polar lipids, and the balance lipid fractions.
  • Additional weight percent fractions can include: from about 40 wt.% to about 50 wt.% neutral lipids, from about 45 wt.% to about 55 wt.% polar lipids, and balance lipid fractions; from about 50 wt.% to about 60 wt.% neutral lipids, from about 35 wt.% to about 45 wt.% polar lipids, and balance lipid fractions; and from about 60 wt.% to about 70 wt.% neutral lipids, from about 25 wt.% to about 35 wt.% polar lipids, and balance glycolipids.
  • the weight percent ratio of polar lipids to neutral lipids can range from about 0.36:1 to about 1.2:1.
  • the nitrogen sources aid in shifting production towards the polar lipids.
  • the proteins can be whole or fractions.
  • Example proteins include amino acids, such as, proteinogenic amino acids, peptides, polypeptides, peptones, carnitine, GABA, L-DOPA, hydroxyproline, and selenomethionine, ornithine, homoserine, lanthionine, 2-aminoisobutyric acid, and dehydroalanine.
  • the proteinogenic amino acids can include: alanine, arginine, asparagines, aspartic acid, cysteine, glutamic acid, giutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and salts thereof.
  • the peptides can include: substance P, kassinin, neurokinin A, eledosin, neurokinin B, VIP, PACAP, Peptide PHI, GHRH 1-24, glucagon, secretin, NPY, PYY, APP, PPY, POMC, enkephalin, prodynorphin, calcitonin, amylin AGG01 , BNP, and lactotripeptkjes.
  • the proteins can also be hydrolyzed proteins, protein hydrolysates, protein isolates, and protein concentrates.
  • the proteins can be added at the start of the fermentation or during exponential growth (see example below).
  • the nitrogen source can be either the above protein sources, including the above amino acids, or can be a separate source such as: glutamate, monosodium glutamate, glutamic acid, ammonia, ammonium hydroxide, ammonium carbonate, ammonium chloride, ammonium nitrate, nitrate, urea, tryptone, peptone, casein, hydrolysate, creatine, com steep liquor, and combinations thereof.
  • glutamate monosodium glutamate, glutamic acid, ammonia, ammonium hydroxide, ammonium carbonate, ammonium chloride, ammonium nitrate, nitrate, urea, tryptone, peptone, casein, hydrolysate, creatine, com steep liquor, and combinations thereof.
  • glutamate monosodium glutamate, glutamic acid, ammonia, ammonium hydroxide, ammonium carbonate, ammonium chloride, ammonium nitrate, nitrate, ure
  • Schizochytrium is cultured in an artificial seawater based fermentation medium containing 25 g L of NaCI; 5 g/L gS0 4 .7H 2 0; 1 g/L of KCI; 200 mg/L of CaCI 2 ; 5 g/L of glucose; 5 g/L of glutamate (N-source); 1 g/L of KH 2 P0 4 ; 5 ml of Pll metals; 1 ml of A-vitamin solution; and 1 ml of antibiotics.
  • the Schizocbytrium cells began exponential growth, whereby the cells multiply at an exponential rate.
  • the glutamate nitrogen source can remain constant at 5 g L (via replacement addition) or can be increased by adding additional bubbled nitrogen, ammonia, ammonia slats, glutamate, protein sources from above, and/or any of the above described nitrogen sources to the fermentation medium above what is required to maintain the initial 5 g/L concentration of glutamate.
  • the cells can be harvested after 3 days of culturing and placed in fresh medium with constant or increased levels of nitrogen and/or protein source.
  • the concentration of nitrogen (in glutamate form) after 3 days can range from about 5 g L to about 15 g/L, including about 7 g L, 9 g/L, 11 g L, and 13 g L. The concentration of nitrogen will vary depending on the source.
  • the concentration of nitrogen can remain elevated throughout the culturing (e.g. higher than 5 g/L), however, this will require adjustments to the other fermentation medium ingredients to maintain proper pH.
  • microbial oil production is shifted towards the polar lipid fractions and away from the neutral lipid fractions.
  • the fermentation medium can also contain additional components such as carbon sources and microbial growth factors.
  • Carbon sources can be glucose, corn starch, ground com, potato starch, wheat starch, molasses, grain, and combinations thereof.
  • Microbial growth factors can be yeast, vitamins, com steep liquor, and combinations thereof, though it should ne noted here that these are added for general nutritive purposes and are not added to influence the composition of the resulting polar lipids within the total lipids.
  • the fermentation medium can also comprise specific enzymes to assist in creating a tailored phospholipid with specific fatty acid-acyl side chains (R 1 -acyl and R 2 - acyl terminal positions on the phospholipid) and polar groups.
  • the enzymes can comprise transferase enzymes that promote acylation of the fatty acids or esterase enzymes that promote esterfication of the fatty acids.
  • the transferase enzymes will assist in replacing the R 1 and/or R 2 -acyi side chains on the phospholipids with a desired R and/or R -acyl side chain.
  • the transferase enzyme in combination with C20 and higher fatty acids (in free, ester or glyceride form), will inhibit C18-acyl fatty acid carbon chains aggregation, thereby promoting C20-acyl or higher fatty acid carbon chain aggregation.
  • the esterase enzyme acts in a similar fashion, however, the rearrangement is done via esterfication and not acylation of the R 1 -acyl and R 2 -acyl terminal positions.
  • Example transferase enzymes can include: acyltransferases, glyceronephosphate O-acyltransferase, and lecithin-chloesterol acyltransferase.
  • Example esterase enzymes can include: lipases and phospholipases, including phospholipase A1 , phospholipase A2, and phospholipase B. The enzymes can be added at the beginning of the culturing or during the exponential growth phase. For example, the enzymes can be combined with the nitrogen source and protein source, and added at the outset.
  • the fermentation medium can comprise phosphodiesterase enzymes, such as phospholipase C and phospholipase D, that promote esterfication of the polar group on the phospholipids.
  • phosphodiesterase enzymes such as phospholipase C and phospholipase D
  • the phosphodiesterase enzyme in combination with a serine moiety such as serine salt or phosphatidylserine
  • the specific chemistry associated with phospholipase C and phospholipase D is known to those skilled in the art.
  • the enzymes can be added at the beginning of the culturing or during the exponential growth phase.
  • the enzymes can be combined with the nitrogen source and protein source, and added at the outset.
  • Phaeodactylum microalgae is cultured in an artificial seawater based fermentation medium containing 25 g/L of NaCI; 5 g/L MgS0 .7H 2 0; 1 g/L of KCI; 200 mg/L of CaCi 2 ; 5 g/L of glucose; 5 g/L of glutamate (N-source); 1 g/L of KH 2 P0 4 ; 5 ml of Pll metals; 1 ml of A-vitamin solution; 1 ml of antibiotics; transferase enzymes; and Krill oil comprising C22 carbon chains (the C22 carbon chains can be present in free fatty acid, esters, or glyceride form).
  • Phaeodactylum is known to produce high concentrations of EPA relative to DHA. After 3 days of culturing at 27°C and a pH of about 7, the Phaeodactylum cells began exponential growth, whereby the cells multiply at an exponential rate. Also, the transferase enzymes in combination with the Krill oil, promote acylation at the R 1 and R 2 -acyt side chains (C20-acyls) via aggregation with C22-acyl chains on the phospholipids being produced. At this point, serine amino-acids in conjunction with a phosphodiesterase enzyme are introduced to the fermentation medium.
  • the serine amino-acids act as both the additional nitrogen source and serine moiety to promote the production of phosphatidylserine.
  • the serine amino acids can be added as the protein source and serine moiety with additional glutamate or similar nitrogen containing salt, as the additional nitrogen source.
  • glutamate, similar nitrogen containing salt, or amino-acid can be added as the additional nitrogen source and marine animal lipids (e.g. Atlantic mackerel) as the serine moiety.
  • multiple combinations of added nitrogen, proteins, and serine moieties can be used.
  • the cells can also be harvested after 3 days of culturing and placed in fresh medium, prior to the addition of the nitrogen source, serine moiety, and phosphodiesterase enzyme.
  • the microorganism can be microalgae, yeast, bacteria, or fungi.
  • the microalgae can include species from the genera Thraustochytrium, Schizochytrium, and Crypthecodinium, including Crypthecodinium cohnii (C. cohnii).
  • members of the class Dinophyceae, Bacillariophyceae, Chlorophyceae, Prymnesiophyceae, and Euglenophyceae can produce suitable phospholipids with high concentrations of DMA.
  • the microalgae can include species from the genera Thraustochytrium Schizochytrium, Phaeodactylum, Nannochioropsis, Porphydrium, and Monodus, including Phaeodactylum tricomulum, Porphyridium cruentum, and Monodus subterranous (described in Chemicals from Microalgae. Edited by Zvi Cohen, Taylor & Francis Ltd., 1999, hereby incorporated by reference in its entirety).
  • Additional microalgae that produce DHA and EPA can include Odentella aurita (described in Braud JP, "Simultaneous culture in pilot tanks of the microalgage Chondrus crispus and the microalgage Odentella aurita producing EPA", 1998), Pavolova lutheri (described in Guiheneuf et al., "Effect of UV stress on the fatty acid and lipid class composition in two marine microalgae: Pavlova lutheri and Odentella aurita", Springer Science and Business, 2010), Isochysis galbana (described in Chemicals from Microalaaqe. edited by Zvi Cohen, Talory and Francis Ltd., 1999), Nannochloropsis (described in Chemicals from Microalaaqe). and Porphyridiu cruentum (described in Chemicals from Microalgae).
  • the microalgae can be Chaetoceros calcitrans, Chaaotoceros gracilis, Nitzichia cloesterium, Skeletonema costatum, Thalassiosira pseudonana, Dunafiella tertiolecta, Nannochloris atomus, Chroomonas salina, Nannochloropsis oculata, Tetraselmis chui, Tetraselmis suecica, Pavlova salina; all described at www.fao.org docrep/003/w3732e w3732e07.htm.
  • the above references are hereby incorporated by reference in their entirety.
  • the microbial oil must be isolated and purified from the above marine biomasses. Impurities, such as bacteria, particulates, and extraction chemicals, are almost always present when the microbial oils are extracted. Extraction of the microbial oil, neutral lipids, and polar lipids from the microalgae can be done using known methods, including polar and non-poiar solvent extraction, spray drying, super critical extraction, centrifuge, enzymatic extraction, mechanical press, extrusion, sonication, decanter extraction, and combinations thereof.
  • One method of extracting polar lipids is to spray dry the marine biomass, which will lyse the cells, and then use a non-polar solvent, such as hexane, to remove the fatty acid polar lipid portion, including the phospholipids.
  • a non-polar solvent such as hexane
  • Another method is to pretreat the biomass to deactivate any potential phospholipase, which would otherwise degrade the phospholipids.
  • the neutral and polar lipids are extracted from the biomass using known techniques, including polar and non-polar solvent extraction, spray drying, super critical extraction, centrifuge, enzymatic extraction, mechanical press, extrusion, and decanter extraction.
  • the polar lipids, including phospholipids are then isolated and purified from the total lipid fraction with water wash, acetone, or other solvents that cause separation of the neutral from polar and glycolipids.
  • the phospholipids are then dried using known methods including wiped-film evaporation.
  • Any bacteria present in the mircobiomass or phospholipid can be inactivated using an anti-bacterial agent or by UHT treatment prior to processing.
  • Particulates can be filtered out using various filtration methods, such as centrifuge, filter press, cyclone filtration, gravity decanter, or filter media. Extraction of the solvents can be removed using flash distillation, evaporation, and gravity decanting.
  • the phospholipids can be combined with additional compounds, such as fat- soluble vitamins (e.g. A, D, E, K, T), CoQ10, and Resveratrol by solubilizing with TPGS.
  • additional compounds such as fat- soluble vitamins (e.g. A, D, E, K, T), CoQ10, and Resveratrol by solubilizing with TPGS.
  • the phospholipids can be combined with additional structured lipids to make a lipid composition.
  • the structured lipid can comprise tailored phospholipids and further comprises a first fatty acid carbon chain derived from a first lipid source, a second fatty acid carbon chain derived from a second lipid source, and a third fatty acid carbon chain derived from a third lipid source. Structured lipids and methods for making the same are disclosed U.S. Provisional Application No. 61/333,173, which is herein incorporated by reference in its entirety.
  • liposomes comprising the above disclosed phospholipids and lipid compositions. Such liposomes are useful in drug delivery and targeted therapeutics. Liposomes and methods for making the same are disclosed in U.S. Provisional Application No. 61/420,962.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne un procédé de fabrication de phospholipides par la culture de microorganismes, dans un milieu de fermentation qui a été manipulé par des ajouts chimiques, biochimiques et enzymatiques. Les ajouts chimiques peuvent comprendre un ajout d'azote pour aider à déplacer une production d'huile microbienne vers des phospholipides. Les ajouts biochimiques comprennent des acides aminés spécifiques et les ajouts d'enzymes comprennent des enzymes transférases, des enzymes estérases et des enzymes phosphodiestérases spécifiques. Les microorganismes peuvent être des microalgues, de la levure, des bactéries ou des champignons.
PCT/US2011/066499 2010-12-21 2011-12-21 Fabrication de phospholipides et manipulation de composition par manipulation de milieu WO2012088276A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425366P 2010-12-21 2010-12-21
US61/425,366 2010-12-21

Publications (2)

Publication Number Publication Date
WO2012088276A2 true WO2012088276A2 (fr) 2012-06-28
WO2012088276A3 WO2012088276A3 (fr) 2012-11-29

Family

ID=46314888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/066499 WO2012088276A2 (fr) 2010-12-21 2011-12-21 Fabrication de phospholipides et manipulation de composition par manipulation de milieu

Country Status (1)

Country Link
WO (1) WO2012088276A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020185858A1 (fr) * 2019-03-12 2020-09-17 Locus Ip Company, Llc Matériaux et procédés de production de phospholipides du type cardiolipines
CN115975823A (zh) * 2022-08-17 2023-04-18 厦门大学 敲除磷脂酶d基因的裂殖壶菌基因工程菌株及其构建方法和应用
US11759544B2 (en) 2018-05-25 2023-09-19 Locus Solutions Ipco, Llc Therapeutic compositions for enhanced healing of wounds and scars

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039758A1 (en) * 1997-02-20 2002-04-04 De Laat Wilhelmus Theodorus Antonius Maria Fermentative production of valuable compounds on an industrial scale using chemically defined media
US20070004014A1 (en) * 2005-06-29 2007-01-04 Yuichiro Tsuji Method for producing l-threonine
US20090004219A1 (en) * 2005-12-29 2009-01-01 Abl Biotechnologies Ltd. Novel Strain of Schizochytrium limacinum useful in the production of lipids and Extracellular Polysaccharides and process thereof
US20100162620A1 (en) * 2008-12-19 2010-07-01 Mccaffrey William Optimization of Algal Product Production through Uncoupling Cell Proliferation and Algal Product Production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039758A1 (en) * 1997-02-20 2002-04-04 De Laat Wilhelmus Theodorus Antonius Maria Fermentative production of valuable compounds on an industrial scale using chemically defined media
US20070004014A1 (en) * 2005-06-29 2007-01-04 Yuichiro Tsuji Method for producing l-threonine
US20090004219A1 (en) * 2005-12-29 2009-01-01 Abl Biotechnologies Ltd. Novel Strain of Schizochytrium limacinum useful in the production of lipids and Extracellular Polysaccharides and process thereof
US20100162620A1 (en) * 2008-12-19 2010-07-01 Mccaffrey William Optimization of Algal Product Production through Uncoupling Cell Proliferation and Algal Product Production

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759544B2 (en) 2018-05-25 2023-09-19 Locus Solutions Ipco, Llc Therapeutic compositions for enhanced healing of wounds and scars
WO2020185858A1 (fr) * 2019-03-12 2020-09-17 Locus Ip Company, Llc Matériaux et procédés de production de phospholipides du type cardiolipines
CN115975823A (zh) * 2022-08-17 2023-04-18 厦门大学 敲除磷脂酶d基因的裂殖壶菌基因工程菌株及其构建方法和应用

Also Published As

Publication number Publication date
WO2012088276A3 (fr) 2012-11-29

Similar Documents

Publication Publication Date Title
Béligon et al. Microbial lipids as potential source to food supplements
CA2656311C (fr) Acide eicosapentenoique (epa) et lipides polaires produits dans des cultures largement heterotrophes
Castejón et al. Enzymatic modification to produce health-promoting lipids from fish oil, algae and other new omega-3 sources: A review
JP4522257B2 (ja) エステル交換油脂またはトリグリセリドの製造方法
EP2585570B1 (fr) Procédé de séparation des acides gras polyinsaturés d'acides gras à chaîne longue insaturés ou moins saturés
JP2014511406A (ja) エイコサペンタエン酸濃縮物
EP2954072B1 (fr) Biomasse de la microalgue schizochytrium mangrovei et son procédé de préparation
CN101037641A (zh) 含有含多不饱和脂肪酸的甘油三酯的油或脂肪的生产方法
JP5678180B2 (ja) 高度精製に適した、エイコサペンタエン酸を含む組成物
WO2012088276A2 (fr) Fabrication de phospholipides et manipulation de composition par manipulation de milieu
US20110274746A1 (en) Therapeutic Liposomes and Methods For Producing and Using the Same
JP2007209272A (ja) 微生物発酵による長鎖高度不飽和脂肪酸を構成要素として含むリン脂質の製造方法
JP2007089522A (ja) 特定の高度不飽和脂肪酸が濃縮された脂肪酸組成物の製造方法
EP2862937A1 (fr) Procédé de production d'une composition contenant un phospholipide, et composition contenant un phospholipide
Mirmehrabi et al. A novel process for isolation and purification of polyunsaturated fatty acids from a thraustochytrid
FR3045069A1 (fr) Procede d'enrichissement de protistes en lipides riches en acides gras polyinsatures, plus particulierement de classe omega 3, et sa mise en oeuvre pour la production de ces lipides
JP2001245688A (ja) ５，１１，１４−エイコサトリエン酸及び／又は５，１１，１４，１７−エイコサテトラエン酸を含有する脂質及びその製造方法
WO2011143229A2 (fr) Compositions lipidiques et lipides structurés contenant des phospholipides, leurs formulations orales, et leurs procédés de préparation
Eshari et al. A review of the fish oil extraction methods and omega 3 concentration technologies.
WO2023152122A1 (fr) Composition comprenant un melange de dna et/ou d'epa et d'un phospholipide d'orgine vegetale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11851076

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11851076

Country of ref document: EP

Kind code of ref document: A2